Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-83

Antisense Therapeutics (ANP) revises the design of a planned clinical trial for its ATL1102 product to bring forward its data reporting capabilities and cut costs

The company had initially planned for the trial’s Data Safety Monitoring Board to complete a “blinded” analysis of the data at the six-month trial pointHowever, this meant Antisense would not have been able to report any statistically analysed efficacy data for the trial at this point

Now , the company plans to take on a six-month dosing trial of the product in non-ambulant boys with Duchenne’s Muscular Dystrophy (DMD), to be followed by a six-month open-label treatment periodAntisense says this will allow it to report important data at the six-month trial point, adding “substantial value” to the clinical program, and has also reduced the trial’s budget Shares in Antisense Therapeutics are down one per cent to 9.9 cents at 3:21 pm AEST
______
Itsa:
Trial starts in the last 1/4 2022
so mid year 2023 we will have a definitive answer that Atl1102 works or dosen’t in Dmd


Option holders will know mid next year …
If the 48c options are worth converting
because..


imo the sp will be over $1++

Anp Board in their wisdom strongly believe that they can repeat the trial results from the previous trial..

People : stop listening to the negative nois
Itsa is happy with the announcement $$$$$